Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia

BMC Psychiatry

Krithika Rajagopalan³  Andrei Pikalov³  Jay Hsu¹  Antony Loebel¹  Mariam Hassan³  George Awad² 

[1] Sunovion Pharmaceuticals, Inc, Fort Lee, NJ, USA;Department of Psychiatry and Mental Health, Humber River Regional Hospital, Toronto, ON, Canada;Sunovion Pharmaceuticals, Inc, Marlborough, MA, USA

关键词: SF-12;    PETiT;    Antipsychotic;    Lurasidone;    Health-related quality of life;   

Others  :  1123751
DOI  :  10.1186/1471-244X-14-53

 received in 2013-07-19, accepted in 2014-02-14,  发布年份 2014

【 摘 要 】

Background

Patients with schizophrenia frequently switch between antipsychotics, underscoring the need to achieve and maintain important treatment outcomes such as health-related quality of life (HRQoL) following the switch. This analysis evaluated HRQoL changes among patients with schizophrenia switched from their current antipsychotic to lurasidone.

Methods

Stable but symptomatic outpatients with schizophrenia were switched from their current antipsychotic to lurasidone in a six-week, open-label trial. HRQoL was assessed using two validated patient-reported measures, the Personal Evaluation of Transitions in Treatment (PETiT) scale and the Short-Form 12 (SF-12). Total and domain scores (psychosocial function and adherence-related attitude) were assessed using the PETiT scale; patients’ mental and physical component summary scores (MCS and PCS) were assessed using the SF-12. Changes in HRQoL from baseline to study endpoint were compared using ANCOVA, with baseline score, treatment, and pooled site as covariates. Changes were assessed among all patients and those switched from specific antipsychotics to lurasidone.

Results

The analysis included 235 patients with data on the PETiT and SF-12 who had received ≥1 dose of lurasidone. Statistically significant improvements were observed from baseline to study endpoint on the PETiT total (mean change [SD]: 3.2 [8.5]) and psychosocial functioning (2.5 [6.9]) and adherence-related attitude (0.7 [2.6]) domain scores (all p ≤ 0.002). When examined by preswitch antipsychotic, significant improvements in PETiT total scores were observed in patients switched from quetiapine, risperidone, aripiprazole, and ziprasidone (all p < 0.03) but not olanzapine (p = 0.893). Improvements on the SF-12 MCS score were observed for all patients (mean change [SD]: 3.7 [11.5], p < 0.001) and for those switched from quetiapine or aripiprazole (both p < 0.03). The SF-12 PCS scores remained comparable to those at baseline in all patient groups.

Conclusions

These findings indicate that patients switching from other antipsychotics to lurasidone experienced statistically significant improvement of HRQoL, based on PETiT scores, within six weeks of treatment. Patient health status remained stable with respect to the SF-12 physical component and showed improvement on the mental component. Changes in HRQoL varied based on the antipsychotic used before switching to lurasidone.

Trial registration

NCT01143077.

【 授权许可】

   
2014 Awad et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Awad AG, Voruganti LNP: Measuring quality of life in patients with schizophrenia – an update. Pharmacoeconomics 2012, 30(3):183-195.
• [2]Patterson TL, Kaplan RM, Jeste D: Measuring the effect of treatment on quality of life in patients with schizophrenia: focus on utility based measures. CNS Drugs 1999, 12(1):49-64.
• [3]Awad AG, Voruganti LNP: The impact of atypical antipsychotics in quality of life on patients with schizophrenia. CNS Drugs 2004, 18(13):877-893.
• [4]Revicki DA, Genduso LA, Hamilton SH, Ganoczy D, Beasley CM: Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomised clinical trial. Qual Life Res 1999, 8(5):417-426.
• [5]Gee L, Pearce E, Jackson M: Quality of life in schizophrenia: a grounded theory approach. Health and Quality of Life Factors 2003, 1:31-40. BioMed Central Full Text
• [6]Kuperberg G, Heckers S: Schizophrenia and cognitive function. Curr Opin Neurobiol 2000, 10:205-2010.
• [7]Shamsi S, Lau A, Lencz T, Burdick KE, DeRosse P, Brenner R, Lindenmayer J-P, Malhotra AK: Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res 2011, 126:257-264.
• [8]Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Schizophr Bull 1999, 25:173-182.
• [9]Briggs A, Wild D, Less M, Reaney M, Dursun S, Parry D, Mukherjee J: Impact of schizophrenia and schizophrenia treated-related adverse events on quality of life: direct utility utilization. Health Qual Life Outcomes 2008, 6:105. BioMed Central Full Text
• [10]Kim E, Levy R, Pikalov A: Personalized treatment with atypical antipsychotic medications. Adv Ther 2007, 24(4):721-740.
• [11]Hellewell JS: Patients’ subjective experiences of antipsychotics: clinical relevance. CNS Drugs 2002, 16(7):457-471.
• [12]Awad AG, Voruganti LN, Heslegrave RJ, Hogan TP: Assessment of the patient’s subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol 1996, 11(2):55-59.
• [13]Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, David CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
• [14]Nyhuis AW, Faries DE, Ascher-Svanum HA, Stauffer VL, Kinon BJ: Predictors of switching antipsychotic medications in the treatment of schizophrenia. BMC Psychiatry 2010, 10:75. BioMed Central Full Text
• [15]Puschner B, Angermeyer MC, Leese M, Thornicroft G, Schene A, Kikkert M, Burti L, Tansella M, Becker T: Course of adherence to medication and quality of life in people with schizophrenia. Psychiatry Res 2009, 165:224-33.
• [16]Falkai P: Limitations of current therapies: why do patients switch therapies? Eur Neuropsychopharmacol 2008, 3:S135-9.
• [17]Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV: Prevalence of and risk factors for medication nonadherence inpatients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002, 63:892-909.
• [18]Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC: Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry 2004, 65(10):1372-6.
• [19]Santone G, Rucci P, Muratori ML, Monaci A, Ciarafoni C, Borsetti G: Attitudes toward medication in inpatients with schizophrenia: a cluster analytic approach. Psychiatry Res 2008, 158(3):324-34.
• [20]Schennach-Wolff R, Jager M, Seemuller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkotter J, Heuser I, Maier W, Lemke MR, Ruther E, Klingberg S, Gastpar M, Moller HJ, Riedel M: Attitude towards adherence in patients with schizophrenia at discharge. J Psychiatr Res 2009, 43(16):1294-301.
• [21]Adelufosi AO, Adebowale TO, Abayomi O, Mosanya JT: Medication adherence and quality of life among Nigerian outpatients with schizophrenia. Gen Hosp Psychiatry 2012, 34:72-9.
• [22]Awad AG, Voruganti LN: New antipsychotics, compliance, quality of life, and subjective tolerability – are patients better off? Can J Psychiatry 2004, 49:297.
• [23]Morken G, Widen JH, Grawe RW: Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008, 8:32-8. BioMed Central Full Text
• [24]Citrome L: Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. Postgraduate Medicine 2011, 123:153-162.
• [25]McEvoy JP, Citrome L, Hernandez D, Cucchiaro J, Hsu J, Pikalov A, Loebel A: Effectiveness of lurasidone in schizophrenia or schizoaffective disorder patients switched from other antipsychotics: a randomized, six-week, open-label study. J Clin Psychiatry 2013, 74(2):170-9.
• [26]Buckley PF: Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. J Clin Psychiatry 2007, 68(6):5-9.
• [27]Citrome L, Nasrallah HA: On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother 2012, 13(11):1599-1613.
• [28]Voruganti L, Awad G: Personal evaluation of transitions in treatment (PETIT) a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophren Res 2002, 56:37-46.
• [29]Ware JE, Kosinski M, Keller SD: A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Medical Care 1996, 34(3):220-233.
• [30]Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, Conley RR: The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010, 10:2-7. BioMed Central Full Text
• [31]Stahl SM: From antipsychotic agents. In Antipsychotics and Mood Stabilizers: Stahl’s Essential Psychopharmacology. 3rd edition. New York: Cambridge University Press; 2008:185-186.
• [32]Awad AG: Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disorders. Expert Rev Pharmacoeconomics Outcomes Res 2010, 10(1):1-4.
• [33]Voruganti L, Cortese L, Oyewumi L, Cernovsky A, Zirul S, Awad A: Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability side-effect profile and impact on quality of life. Schizophr Res 2000, 43(2–3):135-145.
• [34]Papaioannou D, Brazier J, Parry G: How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in schizophrenia? A systematic review. Value Health 2011, 14(6):907-20.
• [35]Ganesan S, Agambaram V, Randeree F, Eggens I, Huizar K, Meuliend D: Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin 2008, 24(1):21-32.
• [36]Kim S-W, Shin I-S, Kim J-M, Lee J-H, Lee Y-H, Yang S-J, Yoon J-S: Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol 2009, 32(5):243-249.
• [37]Weiden PJ, Simpson GM, Potkin SG, O’Sullivan RL: Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 2003, 64(5):580-588.
• [38]Kim S-W, Shin I-S, Kim J-M, Lee S-H, Lee Y-H, Yang S-J, Yoon J-S: Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive functioning in patients with schizophrenia. Hum Psychopharmacol Clin Exp 2009, 24:565-573.
• [39]Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ: Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psych 2009, 9:54.
• [40]Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, Ingenito GG, Aripiprazole study group: Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacol (Berl) 2003, 166(4):391-9.
• [41]Su J, Barr AM, Procyshyn RM: Adverse events associated with switching from conventional antipsychotic drugs or risperidone to olanzapine. J Psychiatry Neurosci 2012, 37(1):E1-E2.